(60) Pousette, A., Hofmarcher, T. (2025) Cancer Dashboard for Portugal. IHE: Lund
(59) Manzano, A., Wilking, N., Svedman, C., Hofmarcher, T. (2025) The development of the cost of cancer in 31 European countries. Journal of Clinical Oncology. 43(16_suppl).
(58) Manzano, A., Svedman, C., Hofmarcher, T., Wilking, N. (2025) Comparator Report on Cancer in Europe 2025 - Disease Burden, Costs and Access to Medicines and Molecular Diagnostics. IHE Report. 2025:2. IHE: Lund.
(57) Haggren, I., Hofmarcher, T. (2025) Cancer Dashboard for Lithuania - Women's cancers. IHE: Lund.
(56) Pousette, A., Hofmarcher, T. (2024) Cancer Dashboard for Italy - Access to Cancer Medicines. IHE: Lund
(55) Malmberg, C., Hofmarcher, T. (2024) Krebs-Dashboard für Österreich. IHE: Lund.
(54) Pousette, A., Hofmarcher, T. (2024) Cancer Dashboard for Greece. IHE: Lund.
(53) Manzano, A., Hofmarcher, T. (2024) Endometrial Cancer - Improving Care and Driving Policy Change. IHE Report. 2024:12. IHE: Lund.
(52) Hofmarcher, T., Berchet, C., Dedet, G. (2024) Access to oncology medicines in EU and OECD countries. OECD Health Working Papers No. 170.
(51) Manxhuka, B., Hofmarcher, T. (2024) Cancer Dashboard for Poland - Lung cancer. IHE: Lund.
(50) Manzano, A., Hofmarcher, T. (2024) Compendium report on global challenges and opportunities to improve the care of women with triple-negative breast cancer. IHE Report. 2024:10. IHE: Lund.
(49) Blidaru, T., ... Hofmarcher, T., ... Dașcă, L. (2024) 2024 Aspen Healthcare & Quality of Life Seminar: forging a blueprint for Romania's healthcare transformation. Journal of Medicine and Life. 17(4): 381-386.
(47) Manzano, A., Gralén, K., Wilking, N., Hofmarcher, T. (2024) Improving breast cancer care in the Middle East and Africa. IHE Report. 2024:6. IHE: Lund.
(46) Manxhuka, B., Gustafsson, A., Hofmarcher, T. (2024) Patient access to treatment in advanced NSCLC - Are European health systems ready to measure what matters?. IHE Report. 2024:5. IHE: Lund.
(45) Manzano, A., Hofmarcher, T. (2024) Improving outcomes for women with triple-negative breast cancer in Latin America - An extended analysis (Spanish version: Mejorando los resultados para mujeres con cáncer de mama triple negativo en América Latina - un análisis extendido). IHE Report. 2024:4, IHE: Lund, Sweden.
(45) Pousette, A., Hofmarcher, T. (2024) Tackling inequalities in cancer care in the European Union. IHE Report. 2024:1. IHE: Lund.
(44) Manxhuka, B., Hofmarcher, T. (2024) Cancer Dashboard for Poland - Women's cancers. IHE: Lund.
(43) Hofmarcher, T., Leppänen, A., Månsdotter, A., Strandberg, J., Håkansson, A. (2024) Societal costs of illegal drug use in Sweden. International Journal of Drug Policy. 123: 104259.
(42) Gustafsson, A., Hjalte, F., Hofmarcher, T. (2023) Samhällets kostnader för spelproblem i Sverige 2021 - En uppdatering. IHE Rapport. 2023:7. IHE: Lund.
(41) Manzano, A., Hofmarcher, T. (2023) Improving outcomes for women with triple-negative breast cancer in Latin America (Spanish version: Mejorando los resultados para las mujeres con cáncer de mama triple negativo en América Latina). IHE Report. 2023:6, IHE: Lund, Sweden.
(40) Hofmarcher, T., Szilagyiova, P., Gustafsson, A., Dolezal, T., Rutkowski, P., Baxter, C., Karamousouli, E. (2023) Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit. ESMO Open. 8(4):101593.
(39) Hofmarcher, T., Manzano, A., Wilking, N., Lindgren, P. (2023) The disease burden and economic burden of cancer in nine countries in the Middle East and Africa. Value in Health Regional Issues. 37, 81-87.
(38) Manzano, A., Hofmarcher, T. (2023) Improving outcomes for women with triple-negative breast cancer in Asia-Pacific. IHE Report. 2023:3, IHE: Lund, Sweden.
(37) Manzano, A., Hofmarcher, T. (2023) Improving the care of women with triple-negative breast cancer. IHE Report. 2023:2, IHE: Lund, Sweden.
(36) Omar, M.I. et al. and IHE (Hofmarcher, T.) as part of the PIONEER Consortium (2023) Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium. Nature Reviews Urology.
(35) Hofmarcher, T., Malmberg, C., Lindgren, P. (2023) A Global Analysis of the Value of Precision Medicine in Oncology - the Case of Non-Small Cell Lung Cancer. Frontiers in Medicine. 10:1119506.
(34) Andersson, E., Hofmarcher, T. (2023) Värdet av tidig behandling av cancer med immunterapi i Sverige – En genomgång av litteraturen. IHE Rapport. 2023:1. IHE: Lund.
(33) Hofmarcher, T., Gustafsson, A., Hjalte, F. (2022) Samhällets kostnader för spelproblem i Sverige 2021. IHE Rapport. 2022:13. IHE: Lund.
(32) Hofmarcher, T., Lindgren, P., Wilking, N. (2022) Cancer Care in Türkiye in a European Context. IHE Report. 2022:10. IHE: Lund.
(31) Hofmarcher, T., Lindgren, P., Wilking, N. (2022) Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe. Journal of Cancer Policy. 34(100362).
(30) Hofmarcher, T., Plug, E. (2022) Specialization in same-sex and different-sex couples. Labour Economics. 77(101995).
(29) Hofmarcher, T., Ramdén, V., Lindgren, P. (2022) Samhällsekonomiska kostnader för narkotikabruk i Sverige. IHE Rapport. 2022:5. IHE: Lund.
(28) Hofmarcher, T., Ericson, O., Lindgren, P. (2022) Cancer in Ireland – Disease Burden, Costs and Access to Medicines. IHE Report. 2022:4. IHE: Lund.
(27) Hofmarcher, T., Lindgren, P., Wilking, N. (2022) Diagnosed but not treated: How to improve patient access to advanced NSCLC treatment in Europe. IHE Report. 2022:2. IHE: Lund.
(26) Hofmarcher, T., Ahmad, A., Lindgren, P., Wilking, N. (2021) Cancer Care in the Middle East and Africa. IHE Report. 2021:9. IHE: Lund.
(25) Beyer, K. et al. and IHE (Hofmarcher, T.) as part of the PIONEER Consortium (2021) The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. European Urology Focus. 7(5):P943-946.
(24) Hofmarcher, T., Lindgren, P., Wilking, N. (2021) Diagnosed with non-small cell lung cancer but not treated. Annals of Oncology. 32(S5):S1025.
(23) Ringborg, U., Berns, A., Celis, J.E., Heitor, M., Hofmarcher, T., et al. (2021) The Porto European cancer research summit 2021. Molecular Oncology. 15(10):2507-2543.
(22) Hofmarcher, T., Keel, G., Lindgren, P. (2021) Cancer care and access to cancer drugs in Asia-Pacific. IHE Report. 2021:3. IHE: Lund.
(21) Hofmarcher, T. (2021) The effect of education on poverty: A European perspective. Economics of Education Review. 83(102124).
(20) Hofmarcher, T. (2021) The effect of paid vacation on health: evidence from Sweden. Journal of Population Economics. 34(3):929–967.
(19) Hofmarcher, T., Romild, U., Spångberg, J., Persson, U., Håkansson, A. (2020) The societal costs of problem gambling in Sweden. BMC Public Health. 20:1921.
(18) Fridhammar, A., Hofmarcher, T., Persson, S. (2020) Cancer i Sverige – Hur mycket beror på påverkbara riskfaktorer? IHE Rapport. 2020:9. IHE: Lund.
(17) Wilking, N., Brådvik, G., Lindgren, P., Svedman, C., Jönsson, B., Hofmarcher, T. (2020) A comparative study on costs of cancer and access to medicines in Europe. Annals of Oncology. 31(Supplement 4):S1197.
(16) Hofmarcher, T., Lindgren, P. (2020) The Cost of Cancers of the Digestive System in Europe. IHE Report. 2020:6. IHE: Lund.
(15) Errea, M., Skedgel, C., Zamora, B.G., Hampson, G., Althin, R., Hofmarcher, T., Lindgren, P., Cookson, G. (2020) Opportunities to Increase Efficiency in Healthcare. Consulting Reports. Office of Health Economics: London.
(14) Hofmarcher, T., Lindgren, P., Wilking, N., Jönsson, B. (2020) The cost of cancer in Europe 2018. European Journal of Cancer. 129(April):41–49.
(13) Hofmarcher, T., Gustafsson, A., Persson, U. (2020) Samhällets kostnader för spelproblem i Sverige. IHE Rapport. 2020:1. IHE: Lund.
(12) Hofmarcher, T., Brådvik, G., Svedman, C., Lindgren, P., Jönsson, B., Wilking, N. (2019) Comparator Report on Cancer in Europe 2019 – Disease Burden, Costs and Access to Medicines. IHE Report. 2019:7. IHE: Lund.
(11) Hofmarcher, T., Brådvik, G., Lindgren, P., Jönsson, B., Wilking, N. (2019) Comparator Report on Cancer in the Nordic Countries – Disease Burden, Costs and Access to Medicines. IHE Report. 2019:2. IHE: Lund.
(10) Hofmarcher, T. (2019) Essays in Empirical Labor Economics. Lund Economic Studies 212. Department of Economics, Lund University.
(9) Hofmarcher, T., Cabrales Alin, D., Linde, C. (2018) Cost Effectiveness of Implementing ESC Guidelines for Treatment of Iron Deficiency in Heart Failure in the Nordic Countries. Scandinavian Cardiovascular Journal. 52(6):348-355.
(8) Jönsson, B., Hofmarcher, T., Lindgren, P., Moen, F., Wilking, N. (2017) Comparator report on patient access to cancer medicines in Europe revisited - A UK perspective. IHE Report. 2017:1. IHE: Lund.
(7) Jönsson, B., Hofmarcher, T., Lindgren, P., Wilking, N. (2016) The cost and burden of cancer in the European Union 1995–2014. European Journal of Cancer. 66(October):162–170.
(6) Lindgren, P., Jönsson, B., Hofmarcher, T., Wilking, N. (2016) Is there a link between value as defined by ESMO-MCBS and uptake of new drugs?. Journal of Clinical Oncology. 34(15_suppl).
(5) Wilking, N., Hofmarcher, T., Lindgren, P., Jönsson, B. (2016) The burden and direct cost of cancer in Europe (EU-28). Journal of Clinical Oncology. 34(15_suppl).
(4) Jönsson, B., Hofmarcher, T., Lindgren, P., Wilking, N. (2016) Comparator report on patient access to cancer medicines in Europe revisited. IHE Report. 2016:4, IHE: Lund.
(3) Wilking, N., Hofmarcher, T., Wilking, U., Jönsson, B. (2016) Drug utilization research in the area of cancer drugs. In: Elseviers, M., Wettermark, B., Almarsdottir, A.B., et al. (editors). Drug Utilization Research: Methods and Applications. Chichester: Wiley-Blackwell; p. 315-327.
(2) Hofmarcher, T., Borg, S. (2015) Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. Journal of Medical Economics. 18(7):492–501.
(1) Hofmarcher, T., Jönsson, B., Wilking, N. (2014) Access to high-quality oncology care across Europe. IHE Report. 2014:2, IHE: Lund.